Tag Archives: MTC

PR Newswire

Ubie’s AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Leave a comment

Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early disease detection and treatment. Collaborations with industry giants like Takeda, Boehringer Ingelheim, and Pfizer exemplify Ubie’s extensive efforts across a broad range of medical conditions, promoting improved patient care through cutting-edge digital health solutions.

NEW YORK, Dec. 5, 2023 /PRNewswire/ — Ubie, a forerunner in the digital health arena, proudly announces a notable achievement that underscores its commitment to revolutionizing healthcare: Ubie’s AI Symptom Checker has been used more than 2 million times in the U.S. since its introduction to the market just over a year ago. This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.

Since Ubie’s expansion into the U.S. market, the company has been focused on empowering individuals to recognize symptoms early and pursue timely healthcare discussions. This process provides users with in-depth insights into their symptoms, a comprehensive analysis of potential diseases, signs to look out for, and the ideal specialist to consult.

As an evidence-based AI company, data lies at the core of Ubie’s operations and Ubie’s unique relationship with its users allows the collection of differentiated quantitative and qualitative data. Based on user feedback, approximately 75% of patients plan to seek professional medical advice after checking their symptoms with Ubie, reflecting Ubie’s ability to promote high-value care. U.S. user stories illustrate the benefits of Ubie’s AI Symptom Checker:

  • A woman in her 30s, experiencing eye pain and dizziness, utilized the Symptom Checker, which suggested possible health concerns and the importance of a medical assessment. She was later diagnosed with multiple sclerosis (MS), validating the importance of early investigation into her symptoms.
  • An 80-year-old man was prompted by Ubie’s AI to consult a pulmonologist, which led to an early diagnosis of lung cancer, emphasizing the Symptom Checker’s role in early detection.
  • A woman in her 50s was guided by the Symptom Checker to seek medical attention for what turned out to be accurate identifications of bone diseases, highlighting the tool’s effectiveness in early symptom identification.
  • A 60s woman with dizziness mentioned, “The questions you asked matched all of my symptoms. Some I didn’t think to mention to my doctor at the time. I will raise them on my next visit. Thank you.”

Kota Kubo, CEO of Ubie, expresses his enthusiasm: “Surpassing 2 million uses in the U.S. in just a year is more than a number—it’s a marker of our growing role in helping Americans promptly address health concerns and seek professional care. Our technology is designed to complement the work of healthcare providers, bridging the gap from initial concern to professional care.”

Ubie’s collaborations with leading pharmaceutical companies demonstrate the effectiveness of digital health in addressing various medical conditions:

  • In Apr 2023, Ubie partnered with Takeda to tackle Hereditary Angioedema (HAE) through digital transformation initiatives (Press Release).
  • In Mar 2023, Ubie and Pfizer facilitated provider visits for over 17,000 OAB patients in Japan through the integration of “Ubie AI Symptom Checker” and “UUI Consultation Room” (Press Release)
  • In Feb 2022, Ubie worked with Boehringer Ingelheim on a project focused on Pulmonary Fibrosis, enhancing awareness and management of this condition (Press Release).

Recent press releases reflect Ubie’s commitment to enhancing the healthcare experience:

  • The launch of Ubie’s new Generative AI feature for doctors, improving medical record documentation with a 90% User Satisfaction rate (Press Release).
  • Partnership with Google’s Android platform “Health Connect (Beta)” as a launch partner in Japan (Press Release).
  • Successful closure of a $45 million Series C funding round and establish of a New York subsidiary (Press Release).

For more information about Ubie and its AI Symptom Checker, please visit Ubie AI Symptom Checker.

Contact:

Ryosei Hatakeyama
Ubie Inc.
1460 Broadway, New York, NY 10036
Email: pr@ubiehealth.com 

Note to Editors: For more details or to arrange an interview with CEO Kota Kubo, please reach out to Ryosei Hatakeyama at the contact information above.

Source: Ubie, Inc.

PR Newswire

Wonder Tech’s Breakthrough in Language Agnostic Voice AI to Bring Scalable Depression Screening to One Billion People Globally

Leave a comment

SINGAPORE, Nov. 29, 2023 /PRNewswire/ — Wonder Technologies PTE. LTD (“Wonder Tech” or “the Company”), a leading AI-driven mental health solutions company based in Singapore, has reached a breakthrough in its acoustics-based AI for depression screening. The AI model, which identifies depression through detecting nuanced vocal changes, has reached an industry-leading 83% in detection accuracy, surpassing the 80% threshold required for clinical depression detection. With this milestone, Wonder Tech has proven its potential to enable a scalable and adaptable diagnostic tool to help the one billion people affected by mental health disorders worldwide.

By analyzing a 60-second voice sample, Wonder Tech’s voice AI platform can detect and continuously monitor the risk of mental health conditions, categorized on varying levels of severity, to enable personalized treatment in a clinically reliable and scalable way.

This breakthrough was achieved in collaboration with Prof. John Wong at the National University Hospital (NUH) as well as Singapore’s top psychology and medical research institutes. Wonder Tech also received financial and clinical support from Singapore’s Ministry of Health to scale out the solution with leading mental health institutes.

Wonder Tech’s AI model is unique in that it’s pure acoustics-based rather than language-based. Since it does not rely on the content of speech and only requires a 60-second voice sample, the AI model can effortlessly adapt to virtually all languages while maintaining clinical accuracy. Additionally, the solution is hardware-independent, allowing implementation on consumer-grade smart devices, such as smartphones. These flexible features address the critical issues of adaptability and scalability, significantly improving accessibility to an accurate and immediate depression diagnostic tool.

Depression can cause psychomotor function changes that impair cognitive and vocal cord functions. The effects are often exhibited in pitch, intensity, aspiration, jitter and other characteristics in voice. Wonder Tech’s acoustics-based AI system can accurately assess for depression by detecting these subtle signs (objective biomarkers) using a large AI model with over 300 million parameters.

Wonder Tech’s solution is the first acoustics-based AI model for depression screening trained using multidimensional, clinically validated datasets following the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V), which is the gold standard for diagnosis of mental health conditions.

Mental health disorders are prevalent worldwide. By 2030, global loss in productivity for major depressive disorder alone is forecasted to reach US$16 trillion. In the U.S., 21% of adults—nearly one in five—experienced a mental health condition in 2020. Similar trends have been observed in the Middle East, where two-thirds of respondents in a McKinsey Health Institute survey reported poor mental health or a mental health condition diagnosis. To broaden the applications of its solution for greater impact, Wonder Tech is working on adapting its AI model to screen for various disorders, including anxiety, bipolar disorder and schizophrenia.

“Socioeconomic barriers continue to hinder access to treatment for the one billion people experiencing mental health disorders worldwide,” said Wendy Wu, Founder and CEO of Wonder Tech. “In Singapore alone, anxiety and depression have been estimated to cost around S$16 billion (US$11.7 billion) in lost productivity annually, the equivalent to 2.9% of the nation’s GDP. Globally, depression and mental health disorders result in a staggering US$1 trillion in lost productivity each year, underscoring an urgent need to improve their care systems.”

Depression has been estimated to have a 65% misdiagnosis rate. To resolve this issue, Wonder Tech has introduced its AI system as a B2B Software-as-a-Service (SaaS) to global healthcare facilities and enable hardware integration. The system is currently integrated with online healthcare platforms for early detection of mental health conditions. This ensures care providers can offer effective and timely personalized mental health treatment. It also couples with existing chronic disease prevention and management systems to improve patients’ mental health, especially for cardiovascular disease and cancer patients, to increase the cure rate and decrease claims for insurance providers. This system has received positive feedback from enterprise employee benefit programs, government healthcare programs for remote areas, postpartum depression prevention programs and senior care communities.

Supported by Singapore’s Ministry of Health & Temasek Foundation, Wonder Tech is currently collaborating with SingHealth in a broader piloting program in Singapore. The Company is preparing its solution for global English-speaking populations.

About Wonder Technology

Wonder Tech is a Voice Al platform for mental health. Our biomarker technology empowers full cycle of mental health solutions from screening, monitoring & personalized solutions for healthcare platforms, online hospitals, employee benefit programs, production safety, and insurance providers.

Learn more at www.wondertech.ai.

Media Contact
Frank Yu
frank@wondertech.ai 

PR Newswire

Lunit Joins as an Associate Partner with the World Economic Forum

Leave a comment

– Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and collaboration in the realm of AI-driven cancer care

SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has expanded its collaboration with the World Economic Forum by joining as an Associate Partner of the forum.

This achievement marks one of the first instances in Asia and among medical AI companies worldwide, where a company has progressively elevated its collaboration with the forum from its initial status as a Technology Pioneer to an Associate Partner. 

Lunit’s journey with the forum began in 2020 when it joined as a member of the Technology Pioneer community, earning recognition as one of the 100 leading global tech companies—the sole Korean company on the prestigious list of the year.

Building upon this foundation, in 2022, Lunit solidified its position as a key player in the global AI-driven healthcare landscape by becoming a member of the forum’s Unicorn community. In this capacity, Lunit shared insights into the future of AI-driven global healthcare during the forum’s events, including annual meetings in Davos, Switzerland and in Tianjin, China.

“As a global platform, the Forum is thrilled to welcome companies like Lunit in their mission to combat cancer through AI and promote the best possible healthcare, contributing to the well-being of individuals in societies and nations,” said Dr. Shyam Bishen, Head of the Centre for Health & Healthcare at the World Economic Forum.

“The partnership extension, especially the unique access to a global platform at the highest level at forum meetings, strongly supports our commitment to advancing the landscape of the entire cycle of cancer care through AI-driven solutions,” said Brandon Suh, CEO of Lunit. “We are excited to harness the network to accelerate our expansion, make significant strides in combating one of the most formidable global health challenges – cancer -, and addressing inequities in healthcare access.”

Lunit’s dedication to forming global alliances aligns with its mission to combat cancer through AI solutions for precision diagnostics and treatment support. The flagship Lunit INSIGHT suite for early detection of chest and breast cancer is now operational in approximately 2,500+ hospitals and medical institutions across 40+ countries, marking significant progress in advancing the field of medical AI.

About Lunit

Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 2,500+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io

About World Economic Forum

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural, and other leaders of society to shape global, regional, and industry agendas. It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial, and not tied to any special interests.

PR Newswire

Linq Wins Samsung Open Collaboration with LLM-Enhanced Underwriting AI Solution

Leave a comment

SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ — Linq, an AI startup, won first place in the 2023 Samsung Open Collaboration, one of the most prestigious startup competitions in South Korea. Linq showcased its AI-powered underwriting solution, which was made possible by its AI risk models and an advanced vector database management platform for large language models (LLMs) such as ChatGPT.

On October 26, 2023, Linq (formerly known as Wecover Platforms) emerged as the winner of the 2023 Samsung Open Collaboration, held in South Korea.
On October 26, 2023, Linq (formerly known as Wecover Platforms) emerged as the winner of the 2023 Samsung Open Collaboration, held in South Korea.

Previously known as Wecover Platforms, Linq secured its win after a 4-month collaboration with Samsung Life Insurance in October. Linq was a standout among the 14 startups that advanced to the final round from an initial pool of 317 participants. This AI Underwriting chat solution, trained and embedded over tens of thousands of pieces of data, not only allows underwriters to evaluate the risk associated with insuring a potential client for cancer insurance but can also explain the reasons behind its results—a feature that was not possible in prior AI-powered underwriting solutions.

For the first time, Linq has successfully demonstrated the combination of advanced AI, including Bayesian neural networks with LLMs. Linq has taken measures to backtrack the significant factors that determine the results in AI models, addressing a notable challenge that previous AI models faced. Their method reflects which factors overcome the limitations of prior AI models that could not explain the reasons for the results by AI. Jacob Choi, Founder and CEO of Linq, stated, “Working closely with South Korea’s leading insurance company gave us access to a wealth of high-quality data. This collaboration reinforced our belief in the power of LLMs to innovate in the underwriting sector.” He continued, “Our goal at Linq is to make it simpler for businesses to integrate their own knowledge with large language models using our advanced vector database management platform.” He also highlighted plans to incorporate multimodal embedding models to deepen the understanding of corporate documents.

About Linq:

Linq is dedicated to building a vector database management platform that empowers companies to harness large language models, unlocking the full potential of their internal knowledge. Linq’s precise and user-friendly API solution is starting to be used by leading legal and insurance firms in South Korea. In addition, it provides solutions for the technical support sector within the US market.

Contact Information:

Jacob Chanyeol Choi, Founder & CEO
jacob.choi@getlinq.com

PR Newswire

Verista Awarded by Frost & Sullivan for Providing Next-Generation Compliance and Quality Management Solutions in the Life Sciences Industry

Leave a comment

Verista supports its clients by implementing pioneering services, solutions and technologies, along with its unwavering client commitment and deep domain expertise

SAN ANTONIO, Sept. 19, 2023 /PRNewswire/ — Frost & Sullivan recently researched the life sciences quality management and compliance solutions and services industry and, based on its findings, recognizes Verista with the 2023 Global Customer Value Leadership Award. Verista is a world-leading business and technology consulting firm that delivers groundbreaking end-to-end solutions to life sciences companies. The company supports pharmaceutical, biotech, medical device, and Contract Development and Manufacturing Organizations (CDMOs) by solving their most pressing challenges across the GxP lifecycle since 1997.

Verista
Verista

Verista’s expertise resides in providing compliance, validation, quality, and systems services that empower its clients to ensure patient safety, facilitate compliance and improve their process efficiencies with results-driven solutions. The company also assists its clients in upgrading their operations, qualifying their systems, improving quality, and ensuring data integrity through its in-depth industry know-how that consistently meets the current market needs and its clients’ expectations.

“Verista is transforming the digital landscape of its clients by implementing next-gen processes and technologies that digitize paper-based activities and enable Pharma 4.0,” said Natalia Casanovas, Best Practices Research Analyst at Frost & Sullivan. “Positioned as a leader in its industry, the company is exceptionally innovative and delivers outstanding results in the life sciences sector, and its unique approach speeds up processes and maximizes results, resulting in superior value for clients.”

The company prides itself on its unconditional compromise with its clients and partners, fulfilling their requirements with the highest dedication, quality, and professionalism. Verista ensures a rapid response to client requirements and issues, enabling timely resolution, minimizing disruptions, accelerating time to market, and allowing clients to seize new market opportunities. For this reason, the company has a 95% client retention rate and has delivered over 2,000 successful projects.

Verista’s commitment to delivering enterprise-wide quality and compliance services ensures its clients succeed and significantly boost efficiency to adjust to the latest market trends. As a result, Verista is rapidly growing and expanding its operations in the European Union and Asia-Pacific regions, further strengthening its global presence.

“Verista’s Managed Service offering provides a 360˚ view of the client’s operations, which ensures continuous course adjustment and delivery improvement, and alignment of its services with client goals and objectives. Additionally, it enhances business continuity, reducing system downtime and enabling clients to concentrate on their mission to deliver products that improve lives,” noted Unmesh Lal, Senior Industry Analyst, Healthcare at Frost & Sullivan.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers, focusing on improving the return on the investment that customers make in its services or products. The award recognizes Verista’s unique focus on augmenting its customers’ value, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Lindsey Whitaker
P: +1 (210) 477-8457
E: lindsey.whitaker@frost.com 

About Verista

Verista is a leading business, technology and compliance company that enables clients to improve health and improve lives. They help clients solve their most critical and complex challenges across the GxP lifecycle, from R&D to manufacturing. Verista’s experts continually deliver consistent, safe, and high-quality results across the product development lifecycle in the areas of enterprise and lab solutions, technology solutions, manufacturing solutions, and regulatory compliance and product management.

Susan Najjar
Susan.najjar@verista.com 

PR Newswire

Mediballoon’s Online Shop is now live, offering a range of medical balloons and tubing for sale. Mediballoon is your best partner for medical device development.

Leave a comment

UNION CITY, Calif., Aug. 9, 2023 /PRNewswire/ — Mediballoon, Inc., a Medeologix company established in 2016 specializing in medical balloon design, development, and scale-up production, is excited to announce the launch of the Mediballoon Online Shop. This newly unveiled platform caters to engineers, designers, and innovators seeking to rapidly prove their concepts in advanced medical devices, by offering a wide array of balloons and tubing products.

Balloon development center of Mediballoon
Balloon development center of Mediballoon

Mediballoon’s online shop features a user-friendly interface that simplifies the process for customers to quickly select diverse processes, materials, shapes, and sizes, all accessible within an expedited timeframe to complete purchases, effectively eliminating uncertainties during development and enhancing the shopping journey. “We understand the eagerness to promptly prove the concept, especially in today’s rapidly evolving environment where time is crucial,” stated Anant Hegde, the founder, and CEO of Mediballoon, Inc. Mediballoon’s online shop ensures rapid shipment within 48 hours, meeting the demands of today’s fast-paced world.

With 25 years of experience, Mediballoon excels in the field of balloon and tubing development. This expertise spans balloon tubing, single lumen catheter tubing, multi-lumen tubing with up to 8 lumens, and heat shrink tubing. Mediballoon’s expertise is now complemented by its comprehensive one-stop-shop service, effectively alleviating numerous challenges engineers encounter. This service includes rapid prototyping, engineering assistance, pilot production, and scale-up production, all aimed at providing straightforward solutions that swiftly transform innovative ideas into tangible medical advancements.

Mediballoon also offers a seamless transition from pilot production to a mass production site in Taiwan. With engineering excellence, sourcing, and supply chain integration, the Taiwan mass production facility enhances cost-effectiveness, improves efficiency, and enables faster responses to market demands. “Whether you need support for quick component development or moving towards mass production, Mediballoon is your best partner in balloon manufacturing and extrusion,” said Hegde.

For more information, please visit:
Mediballoon Online Shop: www.medeologix.com/online-shop
Mediballoon Website: www.medeologix.com/mediballoon

About Mediballoon, Inc.

Mediballoon is an expert in extruding medical tubing and developing medical balloons in different shapes and sizes using various thermoplastic materials including Polyurethane, Polyethylene, Polyvinylidene fluoride (PVDF), Polybutylene terephthalate (PBT), Polyethylene terephthalate (PET), PEBAX, and Nylons.

Mediballoon has received ISO 13485:2016 certification, underscoring their dedication to delivering safe and effective medical solutions for the ultimate benefit of patients.

PR Newswire

TraceLink Accelerates DSCSA 2023 Customer Readiness, Supply Chain Digitalization, and Drug Shortage Predictability in Second Quarter of 2023

Leave a comment

As the industry prepares for DSCSA 2023 regulations, 50% of the US MAH market is now EPCIS-enabled through the TraceLink B2N Integrate-Once network. This digital foundation is allowing them to enhance supply chain visibility, collaboration, and resilience.

BOSTON, July 28, 2023 /PRNewswire/ — TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 290,000 healthcare and life sciences entities through its B2N Integrate-Once™ network, today announced significant business growth and rapidly accelerating network adoption. With the looming Drug Supply Chain Security Act (DSCSA) compliance deadline on November 27, 2023, pharmaceutical supply chain companies continue to expand digital network connections on the TraceLink network to improve supply chain performance and leverage the extensive serialization and track-and-trace network foundation to tackle the ongoing challenges of drug shortages.

Key highlights of the quarter include:

  • 43 new customer accounts and 90 new customer projects initiated for DSCSA compliance.
  • 3,115 network links created across 504 companies on the TraceLink network.
  • Protected 100,000 patients from drug shortages and saved pharmacies millions of dollars in revenue by predicting shortages in advance with Product Availability Intelligence solution.
  • Surpassed one billion DSCSA Transaction Histories processed on the TraceLink network.
  • Surpassed one million DSCSA-compliance EPCIS transactions exchanged between trading partners on the TraceLink network.
  • Launched the Multienterprise Information Network Tower (MINT) solution to power end-to-end, real-time supply chain visibility and multienterprise process collaboration.
  • Launched Supply Chain Work Management for Compliance Exceptions to provide an automated and efficient solution to manage and reconcile DSCSA and other compliance exceptions between trade partners.
  • Hosted more than 200 healthcare and life sciences industry professionals from over 75 companies at 30+ sessions at FutureLink 2023. The TraceLink conference focused on DSCSA 2023 readiness plans, emerging opportunities to address drug shortages by leveraging AI with supply chain data, and building a foundation for supply chain digitalization to drive better end-to-end visibility, collaboration, and intelligence.

Speaking about why Sentara Health chose TraceLink as their DSCSA compliance partner, Tyler Martinson, Pharmacy Manager at Sentara Health, had this to say: “TraceLink was vital to this role, their support, both their IT and just their knowledge of the law. Laws change and rules keep coming out and it was very helpful to have someone who was really focused on that to help explain to us what was coming down the road and what we should be aiming towards.”

TraceLink continues its 10+ year investment in helping companies across the pharmaceutical and healthcare supply chain—from pharmaceutical manufacturer to healthcare provider and retail pharmacy—meet the complex unit-level traceability, verification, and other requirements of track-and-trace regulations like DSCSA while helping those companies improve the predictability, agility, and performance of their supply chain operations. Leveraging the interoperable TraceLink network spanning over 120 countries and over 290,000 authenticated pharmaceutical manufacturers, distributors, retail pharmacies, and healthcare providers, TraceLink has enabled over 15,000 live serialization connections, manages over 41 billion serialized products on its network, processes over 50K ASNs a month, and has saved the pharmaceutical industry more than $4.7B in unnecessary point-to-point integration costs by exchanging critical business transactions on the TraceLink network.

To talk with TraceLink experts about our unique approach to helping companies across the pharmaceutical and healthcare supply chain ensure global compliance with track-and-trace regulations while laying the foundation for end-to-end product orchestration and unsurpassed supply chain performance, please visit tracelink.com.

About TraceLink
TraceLink is the pharmaceutical and life sciences industry’s leading provider of supply chain digitalization through end-to-end product orchestration on the Opus digital network platform. With more than 290,000 network members, Opus connects people, processes, systems, and enterprises into a collective information network for intelligent business execution. TraceLink serialization, global track-and-trace compliance, end-to-end supply chain visibility, and real-time supply chain collaboration solutions empower customers to achieve massive scalability, maintain continuous compliance, and ensure supply through a single connection to our B2N Integrate-Once™ network. TraceLink customers serialize more than one billion units per month across 15,000 connections and process over 50K ASNs a month over our network.

Source: TraceLink, Inc.

PR Newswire

Project Matty: Revolutionizing Care for Children with Autism and ADHD Through AI

Leave a comment

SINGAPORE, July 24, 2023 /PRNewswire/ — Project Matty, a pioneering digital health solution, has been launched by a dedicated mother of an ADHD-diagnosed child and Dr. Pamela Lim, a clinical psychology doctor. Both inspired by their personal experiences and united by their commitment to improve the lives of children with autism and ADHD, they’re harnessing the power of artificial intelligence (AI) for an extraordinary mission.

The co-founders’ personal journeys fuel their resolve to bridge the gap in traditional treatments. Born out of one mother’s determination to help her ADHD-diagnosed son, and Dr. Pamela Lim’s drive to assist others like her own child with autism, Project Matty aims to provide more accessible, effective, and personalized care to children worldwide.

Enter M.A.T.T.Y – an acronym for Managing Autism/ADHD Through Texting to You. It’s an AI system that leverages the simplicity and familiarity of texting. M.A.T.T.Y engages in insightful chats with caregivers, learning about each child’s unique traits, and using this information to create personalized virtual pets. These AI-powered pals provide children with an engaging, safe environment where they can develop essential skills beyond clinical settings.

Dr. Pamela Lim, a stalwart in the field of clinical psychology, emphasizes the core philosophy of Project Matty. “Kids with neurodevelopmental disorders behave differently because their brains process the world differently. They’re not abnormal, just different. By understanding how they perceive the world, we can help them integrate into what may seem a frightening and strange world. Our mission with M.A.T.T.Y is to empower caregivers, who can then empower these amazing kids.”

Project Matty embodies the transformative potential of technology when combined with deep empathy and personal experience. It presents a significant opportunity for investors looking to support an innovative solution with vast societal impact.

Join Project Matty in empowering children with Autism and ADHD to reach their full potential. Together, we can make a difference in their lives and contribute to a more inclusive, supportive world.

For more information about Project Matty, visit www.projectmatty.com. To schedule an interview or for more information, please contact Nora Lam at hello@projectmatty.com

Dr Pamela Lim Bio:

https://www.linkedin.com/in/dr-pamela-lim/?originalSubdomain=sg

PR Newswire

Join Taipei City’s Thriving Health Industry: Registration for “Win A Greater Health” Pitch Contest Starts Now!

Leave a comment

TAIPEI, July 18, 2023 /PRNewswire/ — The Taipei City Government’s Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its “Talent Exchange Program”. In line with this initiative, they have established the “Taipei Entrepreneurs Hub (TEH)” to cultivate a vibrant international community of entrepreneurs in the heart of Taipei. In 2023, the spotlight is on the health industry, and the department is delighted to announce the forthcoming “Win A Greater Health” international online startup pitch contest. Registration is now open until September 15, 2023, Taipei time (UTC+8). International teams specializing in digital health fields are welcomed to participate.

The department places great importance on attracting international startup teams with key technologies and research capabilities to facilitate the cooperative transformation and upgrade of local industries. This has always been a crucial industrial goal for the city government. Additionally, harnessing the power of innovation and entrepreneurship to drive city diplomacy is a significant driving force. Therefore, in recent years, the department has actively connected global startup ecosystem resources through TEH, organizing various networking events across different industries and time zones, creating the most resource-rich and comprehensive entrepreneurial community. The ultimate goal is to welcome international entrepreneurs from around the world to establish their presence in Taipei.

This year, the international startup pitch contest, in collaboration with TEH, the Taiwan Digital Health Industry Development Association, BE Health Ventures, and the Taipei Medical University BioMed Accelerator, welcomes international startup teams to participate. The competition encourages teams to develop Taiwan market expansion plans with a focus on implementing their goals in Taipei City. The winning teams will not only receive one international round-trip ticket from anywhere to Taipei to attend the Demo Day presentation but also enjoy customized matchmaking sessions and business itineraries during their stay in Taipei. Selected teams will have diverse opportunities for technological connections, collaborations, and interactions with businesses and venture capital firms in Taipei.

In addition to organizing the competition, the city government has established StartUp@Taipei office and Inves Taipei office to support startups from around the world in settling in Taipei. The ultimate goal is to make Taipei City a partner for international talents and collaborate to develop more business opportunities.

For more information and registration details for the online competition, you can visit the official Facebook page or LinkedIn page, or contact the organizing company Everiii Consulting CO., Ltd. at (+886 2) 33435456 ext. 806, Ms. Kuo.

PR Newswire

Lunit’s AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists’ Diagnostic Determination – Published in Radiology

Leave a comment

– Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists’ chest X-ray analysis performance

SEOUL, South Korea, July 3, 2023 /PRNewswire/ — Findings from a recent study demonstrate that medical AI solutions with only high diagnostic accuracy can significantly improve the reading performance of radiologists.

Lunit's chest X-ray AI analysis solution 'Lunit INSIGHT CXR'
Lunit’s chest X-ray AI analysis solution ‘Lunit INSIGHT CXR’

Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostics solutions, today announced the publication of a study exploring the impact of medical AI solutions’ accuracy on radiologists’ diagnostic determination. The study, conducted by Seoul National University Hospital from December 2015 to February 2021, was recently published in ‘Radiology,’ a renowned peer-reviewed journal in medical imaging.

The study involved a cohort of 30 doctors, including 20 board-certified radiologists with 5 to 18 years of expertise and 10 radiology residents with 2 to 3 years of training. A total of 120 retrospectively collected chest radiographs were assessed, with 60 obtained from patients with lung cancer and the remaining 60 showing no abnormalities.

During the first session, the 30 readers were divided into two groups and analyzed 120 chest X-rays each without the assistance of AI. In the subsequent session, each group reinterpreted the images with the aid of either a high-accuracy or low-accuracy AI model.

The high-accuracy AI model utilized in the study was Lunit INSIGHT CXR, Lunit’s commercially available AI solution for chest X-ray analysis. In contrast, the low-accuracy model was trained using only 10% of the data available to Lunit INSIGHT CXR. The AUROC (area under the receiver operating characteristic curve), a commonly used metric for diagnostic accuracy, of Lunit INSIGHT CXR was 0.88, while the low-accuracy AI model only reached 0.77.

The study revealed that using the higher-accuracy AI model, Lunit INSIGHT CXR, significantly improved radiologists’ performance. The AUROC was remarkably advanced from 0.77 to 0.82 when assisted by the high-accuracy AI model.

Conversely, the radiologists from the other group did not experience any performance improvement when utilizing the low-accuracy AI model, as the AUROC remained at 0.75. Moreover, the group that employed the high-accuracy AI model demonstrated a higher susceptibility to AI suggestions. The radiologists accepted 67% of AI recommendations that contradicted the initial reading results, compared to 59% acceptance of the group that utilized the low-accuracy AI model.

Moreover, the study findings highlighted that factors such as radiologists’ individual expertise, experience with AI, or attitudes toward AI had negligible impact on their reading performance in the second session. Instead, the accuracy of the AI model and the radiologists’ initial diagnostic accuracy emerged as the primary determinant shaping the final diagnostic determination.

These findings underscore the significance of the AI model’s performance when radiologists use AI as a second reader. Furthermore, the study demonstrates how such AI assistance can increase radiologists’ susceptibility to AI suggestions, ultimately contributing to more accurate diagnoses.

“The study backs that irrespective of radiologists’ individual characteristics, the utilization of high-performance AI significantly enhances diagnostic accuracy and fosters a greater acceptance of AI within medical practices,” said Brandon Suh, CEO of Lunit. “At Lunit, we are committed to developing AI-powered solutions that not only improve patient outcomes but also augment the expertise of healthcare professionals. This publication is a testament to our dedication to advancing the field of cancer diagnostics through cutting-edge technology.”

Radiology, owned and published by the Radiological Society of North America (RSNA), is a prestigious publication with a distinguished Impact Factor of 29.146, making it the number one ranked journal in the field of medical imaging.

About Lunit

Lunit is a deep learning-based medical AI company on a mission to conquer cancer, one of the leading causes of death worldwide. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit focuses on developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing giants like Google, IBM, and Microsoft. As a medical AI company grounded on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship products, Lunit INSIGHT CXR and Lunit INSIGHT MMG, are clinically used in approximately 2,000 hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea with offices and representatives worldwide.